Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia. uri icon

Overview

publication date

  • October 26, 2016

Research

keywords

  • Antineoplastic Agents
  • Molecular Targeted Therapy
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Waldenstrom Macroglobulinemia

Identity

Scopus Document Identifier

  • 84992396734

Digital Object Identifier (DOI)

  • 10.1080/10428194.2016.1247957

PubMed ID

  • 27784188

Additional Document Info

volume

  • 58

issue

  • 6